Search | Clinical Trials Finder

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: MTX-463, Placebo; Biological · Other
Lead sponsor: Mediar Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 23 more

Conditions: Prostate Cancer
Interventions: 70.2 Gy 3D-CRT/IMRT, 79.2 Gy 3D-CRT/IMRT; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2022
U.S. locations: 72
States / cities: Long Beach, California • Sacramento, California • San Francisco, California + 55 more

Conditions: Obesity
Interventions: Enhanced NCP Support, LEAP; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Non Small Cell Lung Cancer
Interventions: Telisotuzumab Vedotin, Docetaxel; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 50
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 46 more

Conditions: Posttraumatic Stress Disorder
Interventions: Family Supported Prolonged Exposure, Standard Prolonged Exposure; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Decatur, Georgia • Ann Arbor, Michigan • Minneapolis, Minnesota

Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 207
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more

Conditions: Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 276
States / cities: Birmingham, Alabama • Aurora, Colorado • Boulder, Colorado + 184 more

Conditions: Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions: Cetuximab, Encorafenib, Nivolumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 282
States / cities: Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more

Conditions: Colorectal Cancer
Interventions: fluorouracil, leucovorin calcium, levamisole hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 1,917 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2008
U.S. locations: 35
States / cities: Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 29 more

Conditions: ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
Interventions: Marqibo; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 28
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 25 more

Conditions: Cardiovascular Disease, Coronary Artery Disease
Interventions: saphenous vein graft, radial artery graft; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 11
States / cities: Birmingham, Alabama • Tucson, Arizona • No. Little Rock, Arkansas + 8 more

Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Oligometastatic Colorectal Carcinoma
Interventions: Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation, Chemotherapy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 188
States / cities: Kingman, Arizona • Phoenix, Arizona • Beverly Hills, California + 146 more

Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 858
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more

Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Positron Emission Tomography, Rituximab, Venetoclax, Zanubrutinib; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 145
States / cities: Tucson, Arizona • Irvine, California • Coral Gables, Florida + 108 more

Conditions: Cancer
Interventions: Internet-based pain coping skills program; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 149
States / cities: Fort Smith, Arkansas • Antioch, California • Dublin, California + 118 more

Conditions: Breast Inflammatory Carcinoma
Interventions: Biospecimen Collection, Olaparib, Radiation Therapy, Survey Administration; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 214
States / cities: Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 174 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 555
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 427 more

Conditions: Colorectal Cancer
Interventions: fluorouracil, leucovorin calcium, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 178
States / cities: Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 114 more

Conditions: Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration; Drug · Procedure · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 338
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 69 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 864
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more

Conditions: Leukemia
Interventions: filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, valspodar; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 56 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 89
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more

Conditions: Crohn's Disease
Interventions: Placebo, CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 73
States / cities: Anaheim, California • Oceanside, California • Poway, California + 42 more

Conditions: Postoperative Pain
Interventions: massage treatment; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: AIDS, HIV Infections
Interventions: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART; Other · Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 29
States / cities: Phoenix, Arizona • Long Beach, California • Palo Alto, California + 26 more

Search by objective public record fields.

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

Learn, Engage, Act, Process (LEAP) for MOVE!

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Improving Veteran Adherence to Treatment for PTSD Through Partnering With Families

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed

Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy

Radial Artery Versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

An Internet-based Program to Help Cancer Survivors Manage Pain

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Massage After Surgery To Help Treat Post-Operative Pain

CSP #512 - Options in Management With Anti-Retrovirals